Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).

Forster M, Hackshaw A, De Pas T, Cobo M, Garrido P, Summers Y, Dingemans AC, Flynn M, Schnell D, von Wangenheim U, Loembé AB, Kaiser R, Lee SM.

Lung Cancer. 2018 Jun;120:27-33. doi: 10.1016/j.lungcan.2018.03.007. Epub 2018 Mar 9.

2.

Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92.

Whelan J, Hackshaw A, McTiernan A, Grimer R, Spooner D, Bate J, Ranft A, Paulussen M, Juergens H, Craft A, Lewis I.

Clin Sarcoma Res. 2018 Mar 30;8:6. doi: 10.1186/s13569-018-0093-y. eCollection 2018.

3.

Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports.

Hackshaw A, Morris JK, Boniface S, Tang JL, Milenković D.

BMJ. 2018 Jan 24;360:j5855. doi: 10.1136/bmj.j5855. Erratum in: BMJ. 2018 Apr 11;361:k1611.

4.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
5.

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy.

Milani A, Kristeleit R, McCormack M, Raja F, Luvero D, Widschwendter M, MacDonald N, Mould T, Olatain A, Hackshaw A, Ledermann JA.

ESMO Open. 2017 Jan 31;1(6):e000117. doi: 10.1136/esmoopen-2016-000117. eCollection 2016.

6.

Reducing the socioeconomic gradient in uptake of the NHS bowel cancer screening Programme using a simplified supplementary information leaflet: a cluster-randomised trial.

Smith SG, Wardle J, Atkin W, Raine R, McGregor LM, Vart G, Morris S, Duffy SW, Moss S, Hackshaw A, Halloran S, Kralj-Hans I, Howe R, Snowball J, Handley G, Logan RF, Rainbow S, Smith S, Thomas M, Counsell N, von Wagner C.

BMC Cancer. 2017 Aug 14;17(1):543. doi: 10.1186/s12885-017-3512-1.

7.

Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards.

Dehbi HM, Royston P, Hackshaw A.

BMJ. 2017 May 25;357:j2250. doi: 10.1136/bmj.j2250. No abstract available.

8.

Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer.

Read ML, Fong JC, Modasia B, Fletcher A, Imruetaicharoenchoke W, Thompson RJ, Nieto H, Reynolds JJ, Bacon A, Mallick U, Hackshaw A, Watkinson JC, Boelaert K, Turnell AS, Smith VE, McCabe CJ.

Oncogene. 2017 Sep 14;36(37):5296-5308. doi: 10.1038/onc.2017.154. Epub 2017 May 15.

9.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

10.

Tracking the Evolution of Non-Small-Cell Lung Cancer.

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium.

N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.

11.

Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trials.

Raine R, Atkin W, von Wagner C, Duffy S, Kralj-Hans I, Hackshaw A, Counsell N, Moss S, McGregor L, Palmer C, Smith SG, Thomas M, Howe R, Vart G, Band R, Halloran SP, Snowball J, Stubbs N, Handley G, Logan R, Rainbow S, Obichere A, Smith S, Morris S, Solmi F, Wardle J.

Southampton (UK): NIHR Journals Library; 2017 Mar.

12.

Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.

Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J.

Int J Cancer. 2017 Jun 15;140(12):2805-2819. doi: 10.1002/ijc.30691. Epub 2017 Mar 27. Review.

13.

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).

Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A.

J Clin Oncol. 2017 May 10;35(14):1506-1514. doi: 10.1200/JCO.2016.69.7391. Epub 2017 Feb 27.

14.

Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.

Glynne-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, Benstead K, Harte RJ, Stewart J, Beare S, Hackshaw A, Kadalayil L; ACT II study group.

Lancet Oncol. 2017 Mar;18(3):347-356. doi: 10.1016/S1470-2045(17)30071-2. Epub 2017 Feb 11. Erratum in: Lancet Oncol. 2017 Apr;18(4):e196.

15.

Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.

Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ.

Leukemia. 2017 May;31(5):1087-1095. doi: 10.1038/leu.2017.39. Epub 2017 Jan 27.

PMID:
28126984
16.

Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).

Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, Anderson JR, Judson I, Litière S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, Le Teuff G.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26457. Epub 2017 Jan 23. Review.

PMID:
28111876
17.

Investigating Subgroup Effects in Randomized Clinical Trials.

Dehbi HM, Hackshaw A.

J Clin Oncol. 2017 Jan 10;35(2):253-254. Epub 2016 Oct 31. No abstract available.

PMID:
28056207
18.

Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).

Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B, Napier M, Singer JM, Ferry D, Lewanski C, Forster M, Rolls SA, Capitanio A, Rudd R, Iles N, Ngai Y, Gandy M, Lillywhite R, Hackshaw A.

J Clin Oncol. 2017 Feb;35(4):402-411. doi: 10.1200/JCO.2016.68.1841. Epub 2016 Nov 28.

PMID:
27893326
19.

Publishing interim results of randomised clinical trials in peer-reviewed journals.

Counsell N, Biri D, Fraczek J, Hackshaw A.

Clin Trials. 2017 Feb;14(1):67-77. doi: 10.1177/1740774516664689. Epub 2016 Nov 26. Review.

PMID:
27889701
20.

Study protocol for a randomised controlled trial of brief, habit-based, lifestyle advice for cancer survivors: exploring behavioural outcomes for the Advancing Survivorship Cancer Outcomes Trial (ASCOT).

Beeken RJ, Croker H, Heinrich M, Smith L, Williams K, Hackshaw A, Hines J, Machesney M, Krishnaswamy M, Cavanagh S, Roylance R, Hill A, Pritchard-Jones K, Wardle J, Fisher A.

BMJ Open. 2016 Nov 23;6(11):e011646. doi: 10.1136/bmjopen-2016-011646.

21.

A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening.

Raine R, Moss SM, von Wagner C, Atkin W, Hans IK, Howe R, Solmi F, Morris S, Counsell N, Hackshaw A, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Seaman H, Thomas M, Smith SG, McGregor LM, Vart G, Wardle J, Duffy SW.

Br J Cancer. 2016 Dec 6;115(12):1479-1486. doi: 10.1038/bjc.2016.365. Epub 2016 Nov 22.

22.

Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin.

Watkins RJ, Imruetaicharoenchoke W, Read ML, Sharma N, Poole VL, Gentilin E, Bansal S, Bosseboeuf E, Fletcher R, Nieto HR, Mallick U, Hackshaw A, Mehanna H, Boelaert K, Smith VE, McCabe CJ.

J Clin Endocrinol Metab. 2016 Dec;101(12):4551-4563. Epub 2016 Sep 7.

23.

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson J, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, Wu BW, Bomalaski JS, Lemoine N, Sheaff MT, Rudd RM, Fennell D, Hackshaw A.

JAMA Oncol. 2017 Jan 1;3(1):58-66. doi: 10.1001/jamaoncol.2016.3049.

PMID:
27584578
24.

Lifestyle in Multiple Myeloma - a longitudinal cohort study protocol.

Heinrich M, Fisher A, Paton B, McCourt O, Beeken RJ, Hackshaw A, Wardle J, Yong K.

BMC Cancer. 2016 Jul 4;16:387. doi: 10.1186/s12885-016-2407-x.

25.

Reducing the Social Gradient in Uptake of the NHS Colorectal Cancer Screening Programme Using a Narrative-Based Information Leaflet: A Cluster-Randomised Trial.

McGregor LM, von Wagner C, Atkin W, Kralj-Hans I, Halloran SP, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Thomas MC, Smith SG, Vart G, Howe R, Counsell N, Hackshaw A, Morris S, Duffy SW, Raine R, Wardle J.

Gastroenterol Res Pract. 2016;2016:3670150. doi: 10.1155/2016/3670150. Epub 2016 Mar 16.

26.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Zer A, Ding K, Lee SM, Goss GD, Seymour L, Ellis PM, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, Tsao MS, Shepherd FA.

J Thorac Oncol. 2016 Mar;11(3):312-23. doi: 10.1016/j.jtho.2015.11.010. Epub 2015 Dec 31.

27.

Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening.

Raine R, Duffy SW, Wardle J, Solmi F, Morris S, Howe R, Kralj-Hans I, Snowball J, Counsell N, Moss S, Hackshaw A, von Wagner C, Vart G, McGregor LM, Smith SG, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Atkin W.

Br J Cancer. 2016 Feb 2;114(3):321-6. doi: 10.1038/bjc.2015.413. Epub 2016 Jan 7.

28.

Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials.

Wardle J, von Wagner C, Kralj-Hans I, Halloran SP, Smith SG, McGregor LM, Vart G, Howe R, Snowball J, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Counsell N, Morris S, Duffy SW, Hackshaw A, Moss S, Atkin W, Raine R.

Lancet. 2016 Feb 20;387(10020):751-9. doi: 10.1016/S0140-6736(15)01154-X. Epub 2015 Dec 9.

29.

A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.

Hoskin P, Sundar S, Reczko K, Forsyth S, Mithal N, Sizer B, Bloomfield D, Upadhyay S, Wilson P, Kirkwood A, Stratford M, Jitlal M, Hackshaw A.

J Natl Cancer Inst. 2015 Aug 4;107(10). pii: djv197. doi: 10.1093/jnci/djv197. Print 2015 Oct.

PMID:
26242893
30.

Research in progress--LungSEARCH: a randomised controlled trial of surveillance for the early detection of lung cancer in a high-risk group.

Spiro SG, Hackshaw A; LungSEARCH Collaborative Group.

Thorax. 2016 Jan;71(1):91-3. doi: 10.1136/thoraxjnl-2015-207433. Epub 2015 Jul 2.

31.

Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy.

Khan I, Morris S, Hackshaw A, Lee SM.

BMJ Open. 2015 Jul 2;5(7):e006733. doi: 10.1136/bmjopen-2014-006733. Erratum in: BMJ Open. 2017 Apr 7;7(4):e006733corr1.

32.

Improving research on the efficacy, effectiveness, and harms of traditional chinese medicine.

Tang JL, Hackshaw A, Lao LX, Liu BY, Chung VC.

Evid Based Complement Alternat Med. 2014;2014:657679. doi: 10.1155/2014/657679. Epub 2014 Dec 22. No abstract available.

33.

Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.

Lee SM, Lewanski CR, Counsell N, Ottensmeier C, Bates A, Patel N, Wadsworth C, Ngai Y, Hackshaw A, Faivre-Finn C.

J Natl Cancer Inst. 2014 Jul 16;106(7). pii: dju151. doi: 10.1093/jnci/dju151. Print 2014 Jul.

34.

Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.

Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C.

PLoS Biol. 2014 Jul 8;12(7):e1001906. doi: 10.1371/journal.pbio.1001906. eCollection 2014 Jul.

35.

Application of methods for central statistical monitoring in clinical trials.

Kirkwood AA, Cox T, Hackshaw A.

Clin Trials. 2013 Oct;10(5):783-806. doi: 10.1177/1740774513494504.

PMID:
24130202
37.

A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.

Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T.

Ann Oncol. 2013 Oct;24(10):2565-70. doi: 10.1093/annonc/mdt247. Epub 2013 Jul 14.

38.

A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer.

McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs MA, Symonds RP, Warwick V, Simonds H, Fernando I, Hammond M, James L, Feeney A, Ledermann JA.

Br J Cancer. 2013 Jun 25;108(12):2464-9. doi: 10.1038/bjc.2013.230. Epub 2013 May 21.

39.

Well-being after radiation therapy in thyroid cancer.

Hackshaw A, Kadalayil L, Mallick U.

N Engl J Med. 2013 Feb 14;368(7):685-6. doi: 10.1056/NEJMc1212592. No abstract available.

40.
41.

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.

Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C.

Lancet Oncol. 2012 Nov;13(11):1161-70. doi: 10.1016/S1470-2045(12)70412-6. Epub 2012 Oct 16.

42.

Exploiting FOXM1-orchestrated molecular network for early squamous cell carcinoma diagnosis and prognosis.

Teh MT, Hutchison IL, Costea DE, Neppelberg E, Liavaag PG, Purdie K, Harwood C, Wan H, Odell EW, Hackshaw A, Waseem A.

Int J Cancer. 2013 May 1;132(9):2095-106. doi: 10.1002/ijc.27886. Epub 2012 Oct 25.

43.
44.

Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies.

Jitlal M, Khan I, Lee SM, Hackshaw A.

Br J Cancer. 2012 Sep 4;107(6):910-7. doi: 10.1038/bjc.2012.344. Epub 2012 Aug 9.

45.

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A.

N Engl J Med. 2012 May 3;366(18):1674-85. doi: 10.1056/NEJMoa1109589.

46.

Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo.

Mallick U, Harmer C, Hackshaw A, Moss L; IoN Trial Management Group.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):159-61. doi: 10.1016/j.clon.2012.01.001. Epub 2012 Feb 7. No abstract available.

PMID:
22316618
47.

Benefits and harms of mammography screening.

Hackshaw A.

BMJ. 2012 Jan 6;344:d8279. doi: 10.1136/bmj.d8279. No abstract available.

PMID:
22228697
48.

Attitudes to participation in a lung cancer screening trial: a qualitative study.

Patel D, Akporobaro A, Chinyanganya N, Hackshaw A, Seale C, Spiro SG, Griffiths C; Lung-SEARCH Investigators.

Thorax. 2012 May;67(5):418-25. doi: 10.1136/thoraxjnl-2011-200055. Epub 2011 Nov 21.

PMID:
22106018
49.

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, Earl H, Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin G.

J Clin Oncol. 2011 Oct 1;29(28):3798-804. doi: 10.1200/JCO.2010.33.5208. Epub 2011 Aug 22.

PMID:
21859991
50.

Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls.

Hackshaw A, Rodeck C, Boniface S.

Hum Reprod Update. 2011 Sep-Oct;17(5):589-604. doi: 10.1093/humupd/dmr022. Epub 2011 Jul 11. Review.

Supplemental Content

Loading ...
Support Center